Diagnostic value of baseline 18 F-FDG PET/CT and peripheral blood inflammatory markers for aggressive lymphoma in non-Hodgkin's lymphoma

基线 18F-FDG PET/CT 和外周血炎症标志物对非霍奇金淋巴瘤侵袭性淋巴瘤的诊断价值

阅读:1

Abstract

PURPOSE: This study aims to investigate the diagnostic value of baseline F18 fluorodeoxyglucose (FDG) PET/computed tomography (CT) parameters and peripheral blood inflammatory markers in aggressive lymphoma of non-Hodgkin lymphoma (NHL) and the correlation between peripheral blood inflammatory markers and maximum standardized uptake value (SUV max ). PATIENTS AND METHODS: We conducted a retrospective analysis including 121 patients with NHL. Patients were divided into aggressive lymphoma group and indolent lymphoma group. Mann-Whitney U test, chi-square test and multivariate stepwise logistic regression were used to analyse. Subsequently, receiver operating characteristic (ROC) curve analysis was conducted to evaluate the diagnostic performance. Additionally, Spearman correlation analysis was utilized to explore the correlation between peripheral blood inflammatory markers and SUV max . RESULTS: Leptin mass criterion uptake value (SUL) max , SUV max , SUV avg , SUV peak , focal SUV max /liver SUV max , focal SUV max / mediastinal SUV max , SUL avg , SUL peak , systemic immune-inflammation (SII), neutrophil ratio, total lesion glycolysis (TLG), neutrophils versus lymphocyte ratio (NLR), plateletto-lymphocyte ratio (PLR), lactate dehydrogenase (LDH) and lymphocyle ratio between two groups were statistically significant ( P  < 0.05). SUV max was an independent influencing factor, and the area under the ROC curve was 0.862. There was a positive correlation between the PLR and SUV max ( r  = 0.239; P  = 0.008). CONCLUSION: PET/CT parameters and peripheral blood inflammatory markers have certain value in the diagnosis of aggressive lymphoma in NHL, among which SUV max is an independent influencing marker and is positively correlated with PLR.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。